Monitor for transaction close (1H 2026) and FDA approval decision for SimpleScreen CRC v1 (mid-2026). The $10.00 PIPE price anchors valuation; any redemption risk could affect pro forma cash. Watch for PROACT-Lung enrollment updates and PCD multiomics readouts in 2H 2026.
Price Chart
Executive Summary
Freenome Holdings held an Analyst Day on May 19, 2026, providing a comprehensive update on its proposed business combination with Perceptive Capital Solutions Corp (PCSC). The transaction is expected to close in 1H 2026 with a post-transaction equity value of ~$1.1B and ~$525M pro forma cash, funded by a $240M PIPE from Perceptive and RA Capital. Freenome highlighted its multiomics AI/ML platform, potential FDA approval for its SimpleScreen CRC v1 test (mid-2026), and partnerships with Exact Sciences (up to $885M) and Roche (up to $209M).
Key Financial Metrics
Key Facts
- Post-transaction equity value ~$1.1B, with ~$525M pro forma cash at closing
- $240M PIPE from Perceptive Advisors and RA Capital at $10.00/share
- SimpleScreen CRC v1 PMA submitted; FDA approval anticipated mid-2026
- CRC v1 sensitivity 81.1%, specificity 90.4% in PREEMPT CRC study (n>40k)
- Exclusive U.S. license with Exact Sciences worth up to $885M ($75M upfront)
- Exclusive license with Roche for ex-US kit version worth up to $209M ($75M upfront note)
- SimpleScreen Lung LDT launch expected 2H 2026; PROACT-Lung IVD study enrolling
- Transaction expected to close in 1H 2026, subject to SEC review and shareholder vote
Financial Impact
Pro forma cash of ~$525M provides runway through 2028, covering commercial launch and pipeline milestones. Potential partner milestones from Exact Sciences ($700M regulatory/market access) and Roche ($134M development) represent significant upside.
Risk Factors
- Regulatory risk: FDA may delay or deny CRC v1 PMA approval
- Redemption risk: PCSC shareholders could redeem shares, reducing trust cash
- Commercialization risk: CRC screening market is competitive (Guardant, Exact Sciences)
- Execution risk: Scaling manufacturing and achieving USPSTF guideline inclusion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001140361-26-022097 |
| Document: 0001140361-26-022097-index-headers.html | 0001140361-26-022097 |
| Document: 0001140361-26-022097-index.html | 0001140361-26-022097 |
| Document: 0001140361-26-022097.txt | 0001140361-26-022097 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 22, 2026 13w ago | 3 | $12.01 | awaiting T+5 | — | — |
Jul 22, 2026 13w ago | 3 | $12.01 | awaiting T+5 | — | — |
Jul 20, 2026 14w ago | 25-NSE | $12.01 | awaiting T+5 | — | — |
Jul 9, 2026 15w ago | 425 | $10.90 $12.00 | ▲ +10.09% | ▲ +10.22% | — |
Jul 9, 2026 15w ago | 425 / 8-K | $10.90 $12.00 | ▲ +10.09% | ▲ +10.22% | — |
Jun 18, 2026 18w ago | 425 | $11.01 $10.93 | ▼ −0.73% | ▲ +1.34% | — |
Jun 18, 2026 18w ago | 8-K | $11.01 $10.93 | ▼ −0.73% | ▲ +1.34% | — |
Jun 18, 2026 18w ago | EFFECT | $11.09 $10.96 | ▼ −1.17% | ▲ +0.49% | — |
Jun 11, 2026 19w ago | S-4/A | $11.40 $11.09 | ▼ −2.72% | ▼ −3.39% | — |
Jun 10, 2026 19w ago | 425 | $11.27 $11.16 | ▼ −0.98% | ▼ −1.41% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers